Loomis, Sayles & Company
AEGR

Loomis, Sayles & Company’s Aegerion Pharmaceuticals AEGR Stock Holding History

Loomis, Sayles & Company’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-168,385
Closed -$14.4M – 811
2013
Q3 		$14.4M Buy
168,385
+2,959
+2% +$251K 0.05% 434
2013
Q2 		$10.5K Buy
+165,426
New +$8.78M 0.04% 467

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's AEGR Position: Q4 2013 in Review

Loomis, Sayles & Company sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 168,385 shares — an estimated $14.4M sold.

Loomis, Sayles & Company first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $14.4M in Q3 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Loomis, Sayles & Company reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Loomis, Sayles & Company sold 168,385 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $14.4M.
  • Loomis, Sayles & Company first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Loomis, Sayles & Company's Aegerion Pharmaceuticals position peaked at $14.4M in Q3 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Loomis, Sayles & Company's 13F filing for Q4 2013, filed 12 Feb 2014.